Abstract

TPS5615 Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) administered at the time of cytoreductive surgery (CRS) for ovarian cancer has the potential to permit immediate regional thera...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Hyperthermic intraperitoneal chemotherapy for treatment of ovarian and primary peritoneal cancer: Single institutional experience
S. Farag ... P. Tabrizian
Gynecologic Oncology | VOL. 137
S. Farag, et. al.S. Farag ... P. Tabrizian
01 Apr 2015
Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer
I.M. Martínez Frutos ... P.J. Galindo Fernández
European Journal of Surgical Oncology | VOL. 37
I.M. Martínez Frutos, et. al.I.M. Martínez Frutos ... P.J. Galindo Fernández
13 Apr 2011
Prolonged Exposition with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) May Provide Survival Benefit after Cytoreductive Surgery (CRS) in Advanced Primary Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
Zoltan Herold ... Attila Marcell Szasz
Cancers | VOL. 14
Zoltan Herold, et. al.Zoltan Herold ... Attila Marcell Szasz
06 Jul 2022
Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy.
P. Parrilla ... D. Wallace
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | VOL. 22
P. Parrilla, et. al.P. Parrilla ... D. Wallace
07 Aug 2019
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation.
Yuankai Shi ... Zhengbo Song
Journal of Clinical Oncology | VOL. 42
Yuankai Shi, et. al.Yuankai Shi ... Zhengbo Song
30 Apr 2024
Erratum: Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study
-
Journal of Clinical Oncology | VOL. -
--
16 Apr 2024
Fruquintinib plus paclitaxel versus paclitaxel as second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma (FRUTIGA): A randomized, multicenter, double-blind, placebo-controlled, phase 3 study.
Rui-Hua Xu ... Weiguo Su
Journal of Clinical Oncology | VOL. 42
Rui-Hua Xu, et. al.Rui-Hua Xu ... Weiguo Su
06 Feb 2024
Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).
Maria-Victoria Mateos ... Vania Hungria
Journal of Clinical Oncology | VOL. 42
Maria-Victoria Mateos, et. al.Maria-Victoria Mateos ... Vania Hungria
06 Feb 2024
View more papers